AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.
|Address:||da Vinci Building, Melbourn Science Park, Melbourn|
|Membership type:||Enhanced Founder (£20,000+VAT pa)|
Our skills focus on the discovery, development and commercialisation of medicines for the treatment of some of the world’s greatest healthcare challenges. Our commitment to making a meaningful difference in healthcare is founded on the pursuit of scientific excellence that addresses unmet patient need. Science is at the heart of AstraZeneca’s future strategy and success – and our aspiration is to achieve scientific leadership.
In March 2013, we announced our UK global R&D centre and corporate headquarters will be based at the Cambridge Biomedical Campus. The new, purpose-built site will be home to around 2000 highly-skilled staff, as part of our plan to create strategic global R&D centres in Britain, the United States and Sweden. This will bring together our small molecule and biologics activity, creating opportunities to capitalise on the promise of small and large molecule combinations, improving pipeline productivity and establishing AstraZeneca as a global leader in biopharmaceutical innovation.
The Biomedical Campus will also become our largest centre for oncology research, as well as hosting our work on cardiovascular and metabolic diseases, respiratory, inflammatory, autoimmune and nervous system conditions. Projects here will also include medicinal chemistry and high-throughput screening, and the facility will accommodate a number of pre-clinical research capabilities.
AstraZeneca has a long-standing presence in the UK and we're proud to be developing the next generation of medicines in Cambridge.
In March 2013, we announced plans to establish a new Global R&D Centre and Corporate Headquarters in Cambridge on the Cambridge Biomedical Campus, the future home to approximately 2,000 employees. In February 2015, Cambridge City Council granted planning permission for our new site.
A global pharmaceutical company with a major UK presence. Through innovation and collaboration we can achieve better health for all.
AstraZeneca and Eli Lilly and Company have announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase I trials as a potential disease-modifying treatment for Alzheimer’s disease (AD). This agreement builds on the existing collaboration related to AZD3293, a BACE inhibitor in two pivotal Phase III trials.
4 January 2017Read in full
Repositive, a software company developing novel tools to improve discovery and access to human genomic research data, and AstraZeneca have announced the inaugural members of the PDX Consortium, which was set up to develop a collaborative, pre-competitive resource, to provide streamlined discovery and access to molecular data from Patient Derived Xenografts (PDXs) for use within oncology research.
7 December 2016Read in full
AstraZeneca and its global biologics research and development arm, MedImmune, will continue the oncology momentum built during 2016 with a strong end-of-year presence at three major congresses.
29 November 2016Read in full
The highest climber in the 2016 Index, AstraZeneca is now ranked seventh overall in providing access to medicine.
15 November 2016Read in full
AstraZeneca announced that it has purchased a biologics manufacturing facility in Longmont, Colorado, USA, from Amgen Inc. This facility will be used to support AstraZeneca’s existing operations at its nearby Boulder site also purchased from Amgen in September of 2015.
12 October 2016Read in full
Drug discovery scientists at AstraZeneca are working with Cambridge neighbours at Microsoft Research to develop new ‘drag and drop’ computer modelling of key signalling pathways in cancer cells, which may dramatically reduce the need for ‘wet’ lab experiments to bring truly personalised treatment to patients.
21 September 2016Read in full
AstraZeneca’s first biologic respiratory medicine met primary and key secondary endpoints in pivotal trials for severe asthma.
5 September 2016Read in full
AstraZeneca announced that it has completed* the commercialisation agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anaesthetics portfolio outside the US.
2 September 2016Read in full
AstraZeneca today announced that it has entered into an agreement with Pfizer Inc. to sell the commercialisation and development rights to its late-stage small molecule antibiotics business in most markets globally outside the US*.
24 August 2016Read in full
AstraZeneca announced that the European Commission (EC) has approved Qtern (saxagliptin/dapagliflozin) tablets for the treatment of type 2 diabetes in all 28 EU member countries plus Iceland, Liechtenstein and Norway. The fixed-dose combination of saxagliptin and dapagliflozin is the first DPP-4i/SGLT-2i combination product to be approved in Europe.
20 July 2016Read in full